echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Phase II clinical study of Aimmune's AR201 for egg allergy completed the first patient randomized group

    Phase II clinical study of Aimmune's AR201 for egg allergy completed the first patient randomized group

    • Last Update: 2020-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Aimmune Therapeuticscompany(http://announced that the first phase II clinical study to evaluate AR201 for egg allergy has been completedAR201 is a biological drug that treats egg allergies through oral immunity and is the second development project to be promoted to Phase II clinical using Aimmune's proprietary oral desensitization immunotherapy (CODIT) platformAR201 is a clinically developed research biologic drug used for oral immunotherapy for egg allergiesAimmune is conducting extensive research on AR201 to make this potential therapy widely availableAimmune has reached an exclusive
    supply of egg protein to Michael Foods, the largest high-value-added egg processor in the United States
    http://The agreement includes all of Michael Foods' egg products worldwide and grants Aimmune the exclusive rights to obtain Michael's egg products for clinical and commercial use for up to 15 years after the potential regulatory approval of AR201 for any egg allergy treatment, prevention or cure
    Aimmune Therapeutics is a bio
    pharmaceuticalpharmaceutical(http:// company focused on developing innovative therapies to treat potentially life-threatening food allergies
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.